Lastly, LoGoFunc predicted a GOF variant in JAK2, p.Val617Phe, which has been hypothesized to confer a proliferative advantage in hematopoietic precursor cells [84] and was associated with myeloproliferative disease in BioMe BioBank. This evidence concerns the gene JAK2 and myeloproliferative disorder.